Review article
Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disorders
Ronald G. Strauss,
Corresponding Author
Ronald G. Strauss
University of Iowa DeGowin Blood Center, University of Iowa Hospitals and Clinics Professor of Pathology and Pediatrics, University of Iowa College of Medicine, Iowa City
Department of Pathology, C250 GH, University of Iowa College of Medicine, Iowa City, IA 52242-1182Search for more papers by this authorRonald G. Strauss,
Corresponding Author
Ronald G. Strauss
University of Iowa DeGowin Blood Center, University of Iowa Hospitals and Clinics Professor of Pathology and Pediatrics, University of Iowa College of Medicine, Iowa City
Department of Pathology, C250 GH, University of Iowa College of Medicine, Iowa City, IA 52242-1182Search for more papers by this authorAbstract
A survey was completed by 25 medical directors at different institutions performing plateletpheresis. The practices of these 25 physicians were analyzed regarding the acceptance/rejection of plateletpheresis donors with a history of cardiac disease/surgery, seizures/epilepsy, cancer, or autoimmune diseases. Although available medical literature documents little risk of these disorders either to donors (i.e., donation reactions) or to transfusion recipients (i.e., disease transmission), up to 24% of medical directors outright reject some of these potential donors while others accept patients/donors with these illnesses, providing they meet certain medical/health criteria. Acceptance/rejection of individuals with medical disorders has relevance for the availability of the blood supply and blood product shortages because several million Americans, diagnosed with these illnesses, represent a sizable pool of potential blood and platelet donors. J. Clin. Apheresis 17:111–117, 2002. © 2002 Wiley-Liss, Inc.
REFERENCES
- 1 Newman B. Donor reactions and injuries from whole blood donations. Transfus Med Rev 1997; 11: 64–75.
- 2 Spiess BD, Sassetti R, McCarthy RJ, Narbone RF, Tuman KJ, Ivankovich AD. Autologous blood donation: hemodynamics in a high-risk patient population. Transfusion 1992; 32: 17–22.
- 3 Kasper SM, Baumann M, Radbruch L, Harnischmacher U, Ohler JP, Buzello W. A pilot study of continuous ambulatory electrocardiography in patients donating blood for autologous use in elective coronary artery bypass grafting. Transfusion 1997; 37: 829–835.
- 4 Kasper SM, Ellering J, Stachwitz P, Lynch J, Grunenberg R, Buzello W. All adverse events in autologous blood donors with cardiac disease are not necessarily caused by blood donation. Transfusion 1998; 38: 669–673.
- 5 Cove H, Matloff, J, Sacks JH, Sherbecoe R, Goldfinger D. Autologous blood transfusion in coronary artery bypass surgery. Transfusion 1976; 16: 245–248.
- 6 Mann M, Sacks HJ, Goldfinger D. Safety of autologous blood donation prior to elective surgery for a variety of potentially “high-risk” patients. Transfusion 1983; 23: 229–232.
- 7 Owings DV, Kruskall MS, Thurer RL, Donovan LM. Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use. JAMA 1989; 262: 1963–1968.
- 8 Hillyer CD, Hart KK, Lackey III DA, Lin LS, Bryan JA. Comparable safety of blood collection in “high-risk” autologous donors versus non-high-risk autologous and directed donors in a hospital setting. Am J Clin Pathol 1994; 102: 275–277.
- 9 Gomes M, Araújo T, Castro L, Melo JQ. Autologous blood donation in cardiac patients. Transfus Sci 1995; 16: 269–272.
- 10 Goldfinger D, Capon S, Czer L, Leibfreid J, Trento A, Ross D, Waters P, Klapper E, Pepkowitz S. Safety and efficacy of preoperative donation of blood for autologous use by patients with end-stage heart or lung disease who are awaiting organ transplantation. Transfusion 1993; 33: 336–340.
- 11 Klapper E, Pepkowitz SH, Czer L, Inducil C, Scott L, Goldfinger D. Confirmation of the safety of autologous blood donation by patients awaiting heart or lung transplantation. A controlled study using hemodynamic monitoring. J Thorac Cardiovasc Surg 1995; 110: 1594–1599.
- 12 Dzik WH, Fleisher AG, Ciavarella D, Karlson KJ, Reed GE, Berger RL. Safety and efficacy of autologous blood donation before elective aortic valve operation. Ann Thorac Surg 1992; 54: 1177–1181.
- 13 Morse EE, Jacobs B. Blood donation and its aftereffects. American Scientist 1985; 73: 69–69.
- 14 Lin JTY, Ziegler DK, Lai C-W, Bayer W. Convulsive syncope in blood donors. Ann Neurol 1982; 11: 525–528.
- 15 Kasprisin DO, Glynn SH, Taylor F, Miller KA. Moderate and severe reactions in blood donors. Transfusion 1992; 32: 23–26.
- 16 Ruetz PP, Johnson SA, Callahan R, Meade RC, Smith JJ. Fainting: A review of its mechanisms and a study in blood donor. Medicine 1997; 46: 363–384.
- 17 van der Linden GJ, van Heukelom LHS, Meinardi H. Blood donation, a risk for epileptic patients? Vox Sang 1986; 51: 148–151.
- 18 Silvani C, Zanella A, Rossi F, Cabrini G, Ferrari C, Cesana B, Sirchia G. Effects of blood donation on cerebral blood flow velocity. Transfusion 1990; 30: 710–713.
- 19 Krumholz A, Ness PM, Hauser WA, Douglas DK, Gibble JW. Adverse reactions in blood donors with a history of seizures or epilepsy. Transfusion 1995; 35: 470–474.
- 20 Dzik WH, Okayama A. Can blood transfusion transmit disease-producing genes? Transfusion 1999; 39: 795–800.
- 21
Greenwald P,
Woodard E,
Nasca PC,
Hempelmann L,
Dayton P,
Maksymowicz G,
Blando P,
Hanrahan Jr LR,
Burnett WS.
Morbidity and mortality among recipients of blood from preleukemic and prelymphomatous donors.
Cancer
1976;
38:
324–328.
10.1002/1097-0142(197607)38:1<324::AID-CNCR2820380147>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 22 Vargas SO, Cannon ME, Benjamin RJ, Longtine JA. Transfusion with blood from a donor with chronic myelogeneous leukemia: persistence of the bcr/abl translocation in the recipient. Transfusion 1999; 39: 387–391.
- 23 Witherspoon RP, Schubach W, Neiman P, Martin P, Thomas ED. Donor cell leukemia developing six years after marrow grafting for acute leukemia. Blood 1985; 65: 1172–1174.
- 24 Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, Tratkiewicz JA, Thaler J, Huber C. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 1990; 322: 1794–1946.
- 25 Bloom RE, Brennan JK, Sullivan JL, Chiganti RSK, Dinsmore R, O'Reilly R. Lymphoma of host origin in a marrow transplantation recipient in remission of acute myeloid leukemia and receiving Cyclosporin A. Am J Hematol 1985; 18: 73–83.
- 26 Penn I. Transmission of cancer with donor organs. Transplant Proc 1988; 20: 739–740.
- 27 Baquero A, Fotte J, Kottle S, Raja R, Mendez M, Noumoff J, Cavarocchi N, Cohn JB, Bannett AD. Inadvertent transplantation of choriocarcinoma into four recipients. Transplant Proc 1988; 20: 98–100.
- 28 Loh E, Couch FJ, Hendricksen C, Farid L, Kelly P, Acker MA, Tomaszewski JE, Malkowicz SB, Weber BL. Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation. JAMA 1997; 277: 133–137.
- 29 Wilson LJ, Horvat RT, Tilzer L, Meis AM, Montag L, Huntrakoon M. Identification of donor melanoma in a renal transplant recipient. Diagn Mol Pathol 1992; 1: 266–271.
- 30 Gärtner HV, Seidel C, Luckenbach C, Schumm G, Seifried E, Ritter H, Bültmann B. Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. N Engl J Med 1996; 335: 1494–1496.
- 31 Gugel EA, Sanders ME. Needle-stick transmission of human colonic adenocarcinomas. N Engl J Med 1986; 315: 1487.
- 32 Saarinen, UM. Transfer of latent atopy by bone marrow transplantation? A case report. J Allergy Clin Immunol 1984; 74: 196–200.
- 33 Agosti JM, Sprenger JD, Lum LG, Witherspoon RP, Fisher LD, Storb R, Henderson Jr WR. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N Engl J Med 1988; 319: 1623–1628.
- 34 Lampeter EF Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, Grosse-Wilde H, Gries FA, Kolb H. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341: 1243–1244.
- 35 Mariette X, Cazals-Hatem D, Warszaski J, Liote F, Balandraud N, Sibilia J, and the investigators of the Club Rheumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909–3915.
Citing Literature
